Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.52 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829960 | 0.88 | CYP17A1 (0.56) | NAMPTNPC1RAB9AHDAC1CYP17A1 | |
| SCHEMBL5224586 | 0.88 | NAMPT (0.55) | NAMPTHDAC1NTRK1MAPT | |
| SCHEMBL5224230 | 0.87 | NAMPT (0.48) | NAMPTMKNK1MKNK2NPC1RAB9A | |
| SCHEMBL2133263 | 0.87 | ABCB1 (0.54) | NAMPTMKNK1MKNK2ABCB1HDAC1 | |
| SCHEMBL2606716 | 0.87 | NAMPT (0.54) | NAMPTMKNK1MKNK2ABCB1HDAC1 | |
| SCHEMBL2132251 | 0.86 | ABCB1 (0.56) | NAMPTMKNK1MKNK2LMNAABCB1 | |
| SCHEMBL2832030 | 0.86 | NAMPT (0.49) | NAMPTNPC1RAB9AHDAC1CYP17A1 | |
| SCHEMBL8292317 | 0.85 | HDAC1 (0.56) | NAMPTMKNK1MKNK2ABCB1HDAC1 | |
| SCHEMBL2828932 | 0.85 | NAMPT (0.52) | NAMPTABCB1CYP17A1 | |
| SCHEMBL2606718 | 0.83 | ABCB1 (0.55) | NAMPTMKNK1MKNK2ABCB1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1495002-B1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-8247562-B2 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2012-08-21 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| CN-101805309-A | Benzamide derivatives as histone deacetylase inhibitors | ASTRAZENECA AB | 2010-08-18 | — | — | CN | disclosed |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| CN-1642915-A | Benzamide derivatives useful as inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| EP-1495002-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astrazeneca AB (SE) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087057-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | HDAC3, HDAC1, HDAC4 | NAMPT 1141/4885MKNK1 3525/4885MKNK2 3403/4885 |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | NAMPT 1033/4885MKNK1 3401/4885MKNK2 3223/4885 |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | NAMPT 1040/4885MKNK1 3475/4885MKNK2 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.